Last reviewed · How we verify
Human-derived stromal cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Human-derived stromal cells (Human-derived stromal cells) — Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Human-derived stromal cells TARGET | Human-derived stromal cells | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Human-derived stromal cells CI watch — RSS
- Human-derived stromal cells CI watch — Atom
- Human-derived stromal cells CI watch — JSON
- Human-derived stromal cells alone — RSS
Cite this brief
Drug Landscape (2026). Human-derived stromal cells — Competitive Intelligence Brief. https://druglandscape.com/ci/human-derived-stromal-cells. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab